22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The role of the compliance professional and the compliance function in a corporation has steadily gr...
Read More >
Employers must understand what they can and cannot do now that the Social Security Administration (S...
Read More >
The UK hydraulic fracturing industry has been in the spotlight recently as operators push for higher...
Read More >
Charges of discrimination filed with the Equal Employment Opportunity Commission (“EEOC”) (and sim...
Read More >
Dechert partnered with Getting the Deal Through and Law Business Research on their annual Market Int...
Read More >
This quarter’s issue includes summaries and associated court opinions of selected cases principally...
Read More >